Copyright © 2024 Research Nester. All Rights Reserved
Dystonia Drugs Market size was over USD 872.19 million in 2023 and is anticipated to reach USD 1.72 billion by 2036, growing at around 5.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of dystonia drugs is assessed at USD 909.87 million. The growth of the market can be attributed to the growing prevalence of dystonia disorders, increasing number of incidences of musculoskeletal disorders, and rise in healthcare expenditure in developed nations. According to the World Health Organization, approximately 1.71 billion people have musculoskeletal conditions worldwide. Among musculoskeletal disorders, low back pain causes the highest burden with a prevalence of 568 million people. Apart from these, surge in demand for novel therapies for the treatment of metabolic disorders and rise in investments to improve the overall course of diagnosis and treatment of dystonia are also expected to be crucial factors driving dystonia drugs market growth in the forthcoming years. Furthermore, escalating public awareness about the disease, and improvements in healthcare infrastructure in emerging economies are projected to offer profitable growth opportunities to the market in the near future.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
5.4% |
|
Base Year Market Size (2023) |
USD 872.19 million |
|
Forecast Year Market Size (2036) |
USD 1.72 billion |
|
Regional Scope |
|
The market is segmented by treatment into oral therapy, intravenous, surgery and others, out of which, the oral therapy segment is anticipated to hold the largest share in the global dystonia drugs market on account of the fact that most of the medications for dystonia such as Valium, trihexyphenidyl and Klonopin are prescribed via oral mode of dosage, and the non-invasiveness, patient compliance and convenience of this type of drug administration. Moreover, on the basis of end user, the segment for hospitals is predicted to acquire the largest share over the forecast period, which can be credited to the high preference of patients to choose hospital facilities for treatment as a result of patient satisfaction and rising outpatient services. Larger patient admission in hospitals is also evaluated to drive growth to the market segment by the end of the year 2030.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
By Treatment |
|
|
By End User |
|
On the basis of geographical analysis, the dystonia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is expected to dominate majority revenue share by 2036, on the back of increase in the geriatric population, large patient pool, and rapid growth of pharmaceutical sector in countries such as China, Japan and India. As per another report by the WHO, the total percentage of people aged 60 or above was 9.8 percent in 2017, which is evaluated to increase up to 13.7 percent and 20.3 percent by the end of 2030 and 2050. Additionally, the market in North America is projected to grab the largest share during the forecast period, which can be ascribed to the rising private and venture funding in the healthcare sector in the United States, and growing improvements in reimbursement policies. Along with these, strong presence of prominent medical companies is also anticipated to boost the growth of the region’s dystonia drugs market in the coming years.
· October 14, 2020- Revance Therapeutics, Inc. reported positive results from its ASPEN-1 Phase 3 trial of DaxibotulinumtoxinA for injection in treating cervical dystonia, which is a chronic condition affecting neck muscles.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?